Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Equity Ratio: 2014-2025

Historic Equity Ratio for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to -1.01.

  • ImmunityBio's Equity Ratio rose 50.51% to -1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -1.01, marking a year-over-year increase of 50.51%. This contributed to the annual value of -1.28 for FY2024, which is 9.77% down from last year.
  • ImmunityBio's Equity Ratio amounted to -1.01 in Q3 2025, which was up 28.83% from -1.42 recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Equity Ratio registered a high of -0.52 during Q4 2021, and its lowest value of -2.22 during Q2 2023.
  • Over the past 3 years, ImmunityBio's median Equity Ratio value was -1.55 (recorded in 2023), while the average stood at -1.53.
  • As far as peak fluctuations go, ImmunityBio's Equity Ratio plummeted by 978.39% in 2021, and later spiked by 50.51% in 2025.
  • ImmunityBio's Equity Ratio (Quarterly) stood at -0.52 in 2021, then slumped by 138.65% to -1.24 in 2022, then increased by 6.26% to -1.16 in 2023, then fell by 9.77% to -1.28 in 2024, then soared by 50.51% to -1.01 in 2025.
  • Its Equity Ratio stands at -1.01 for Q3 2025, versus -1.42 for Q2 2025 and -1.95 for Q1 2025.